Pharmacodynamic response to HER2/CD3 bispecific antibody (HER2-TDB): evidence of T-cell recruitment and further rationale for combination treatment with anti-PD-L1

被引：0
|
作者：
Li, Ji
Hristopoulos, Maria
Clark, Robyn
Johnston, Jennifer
Slaga, Dion
Wang, Bu-Er
Cubas, Rafael
Totpal, Klara
Junttila, Melissa R.
Junttila, Teemu T.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1486
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1486
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer
    Lum, Lawrence G.
    Al-Kadhimi, Zaid
    Deol, Abhinav
    Kondadasula, Vidya
    Schalk, Dana
    Tomashewski, Elyse
    Steele, Patricia
    Fields, Kristie
    Giroux, Melissa
    Liu, Qin
    Flaherty, Lawrence
    Simon, Michael
    Thakur, Archana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
  • [22] Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo
    Han, Huamin
    Ma, Juan
    Zhang, Keming
    Li, Wei
    Liu, Changzhen
    Zhang, Yu
    Zhang, Ganlin
    Ma, Pan
    Wang, Lei
    Zhang, Ge
    Tao, Hua
    Gao, Bin
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2446 - 2454
  • [23] Fate and function of anti-CD3 activated T cells (ATC) armed with OKT3 x anti-Her2/Neu bispecific antibody (Her2Bi) in patients with Her2/neu+ tumors
    Lum, L
    Grabert, R
    Gall, J
    Kouttab, N
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S21 - S21
  • [24] BIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Kudla, A.
    Adiwijaya, B.
    Paragas, V.
    Richards, D.
    Braiteh, F.
    Garcia, A. A.
    Denlinger, C. S.
    Conkling, P.
    Edenfield, W. J.
    Anthony, S.
    Hellerstedt, B.
    Raju, R.
    Becerra, C.
    Harb, W.
    Smith, D.
    Kawash, K.
    Frye, S.
    McDonagh, C. F.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2014, 25
  • [25] Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice
    Ozverel, Cenk Serhan
    Uyanikgil, Yigit
    Karaboz, Ismail
    Nalbantsoy, Ayse
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2020, 42 (04) : 346 - 357
  • [26] The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-L1
    Lee, Eunjung
    Park, Young Bong
    Choi, Minji
    Shin, Jangwoo
    Kim, Kyong Bae
    Park, Ju Young
    Kim, Junhwan
    Ahn, Kyoung Kyu
    Lee, Yangsoon
    Park, Kyeongsu
    Son, Wonjun
    Yeom, Donghoon
    Eon, Jaehyun
    Lee, Hanbyul
    Jung, Hanbyul
    Won, Jonghwa
    Oh, Se-Woong
    Kim, Yeul Hong
    CANCER RESEARCH, 2024, 84 (06)
  • [27] Enhanced efficacy of redirected T-cell therapy of TNBC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor
    Rossi, E. A.
    Chang, K.
    Cardillo, T. M.
    Rossi, D. L.
    Li, R.
    Mostafa, A.
    Sharkey, R. M.
    Goldenberg, D. M.
    CANCER RESEARCH, 2017, 77
  • [28] Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
    Wuellner, Ulrich
    Klupsch, Kristina
    Buller, Fabian
    Attinger-Toller, Isabella
    Santimaria, Roger
    Zbinden, Irene
    Henne, Patricia
    Grabulovski, Dragan
    Bertschinger, Julian
    Brack, Simon
    ANTIBODIES, 2015, 4 (04) : 426 - 440
  • [29] Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial
    Liu, Jieqiong
    Song, Chuangui
    Wang, Xiangcai
    Ni, Mingli
    Wang, Xujuan
    Chen, Lei
    Yang, Hongwei
    Zhao, Rusen
    Xu, Ting
    Shen, Lin
    CANCER RESEARCH, 2022, 82 (04)
  • [30] Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
    Liu, Jiayu
    Wu, Xiaoqiong
    Lin, Limin
    Pan, Haitao
    Wang, Yanlan
    Li, Yumei
    Zhao, Yining
    Wang, Zhong
    MOLECULAR THERAPY-ONCOLYTICS, 2019, 14 : 66 - 73
12345